| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000030917 |
| Receipt No. | R000035302 |
| Scientific Title | The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer |
| Date of disclosure of the study information | 2018/02/15 |
| Last modified on | 2019/07/24 (Ver. 7) |
| Basic information | ||
| Public title | The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer | |
| Acronym | The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer (Pre-BICA) | |
| Scientific Title | The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer | |
| Scientific Title:Acronym | The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer (Pre-BICA) | |
| Region |
|
|
| Condition | ||
| Condition | Biliary cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To validate the accuracy of MDCT diagnosis of the pathological TNM stage of biliary cancer, that fulfills the inclusion criteria of the future phase III trial (preoperative therapy + surgery vs. surgery alone) planned in HBP group of Japan Clinically Oncology Group (JCOG) |
| Basic objectives2 | Others |
| Basic objectives -Others | Validation study |
| Trial characteristics_1 | Others |
| Trial characteristics_2 | Others |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | The proportion of pathological stage I (stage IA in distal bile duct cancer) among the patients who were diagnosed with a biliary cancer that fulfills the inclusion criteria of preoperative therapy trial on MDCT |
| Key secondary outcomes | Sensitivity and specificity of MDCT to diagnose a biliary cancer that fulfills the inclusion criteria of preoperative therapy trial; Sensitivity and specificity of MDCT to diagnose the lymph node metastasis; Sensitivity and specificity of MDCT to diagnose the R1 (invasive cancer) or R2 resection |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who fulfills all the following inclusion criteria
1) The patient is diagnosed with adenocarcinoma of biliary tract by pathological examination of resected or pre-/intra- operative biopsied specimen (The pathological diagnosis is conducted according to the sixth edition of General Rules for the Clinical and Pathological Study of Primary Liver Cancer in intrahepatic bile duct cancer, and according to the sixth edition of Classification of Biliary Tract Cancers in other biliary cancers) 2) The patients who underwent the contrast-enhanced multidetector-row computed tomography (MDCT) examination (5mm or less slice, regardless the presence or absence of biliary drainage) within 60 days before operation, and were diagnosed with resectable biliary cancer (without distant metastasis and R0/1 resection possible) 3) The patients underwent laparotomy with the intent of tumor resection between 2014 and 2016 in the institution of JCOG (including not only the resected cases but also the unresected cases) 4) The patients do not have a past history of either preoperative chemotherapy or radiation therapy in the upper abdomen |
|||
| Key exclusion criteria | 1) The patients with intrahepatic bile duct cancer with the macroscopic appearance of periductal infiltrating type, intraductal-growth type or predominant type of either, because General Rules for the Clinical and Pathological Study of Primary Liver Cancer is not applied to these types.
2) The patients who underwent preoperative image examination only in other hospital 3) The patents who have other active cancers at the time of operation |
|||
| Target sample size | 1000 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | National Cancer Center Hospital | ||||||
| Division name | Hepatobiliary and Pancreatic Surgery Division | ||||||
| Zip code | 104-0045 | ||||||
| Address | 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan | ||||||
| TEL | 03-3542-2511 | ||||||
| kshimada@ncc.go.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | National Cancer Center Hospital | ||||||
| Division name | Hepatobiliary and Pancreatic Surgery Division | ||||||
| Zip code | 104-0045 | ||||||
| Address | 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan | ||||||
| TEL | 03-3542-2511 | ||||||
| Homepage URL | |||||||
| sanara@ncc.go.jp | |||||||
| Sponsor | |
| Institute | The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japan Agency for Medical Research and Development |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Institutional review board of National Cancer Center Hospital |
| Address | 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan |
| Tel | 03-3542-2511 |
| NCC_IRBoffice@ml.res.ncc.go.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 札幌厚生病院(北海道)
北海道大学病院(北海道) 手稲渓仁会病院(北海道) 東北大学病院(宮城県) 栃木県立がんセンター(栃木県) 自治医科大学(栃木県) 埼玉県立がんセンター(埼玉県) 国立がん研究センター東病院(千葉県) 千葉大学医学部(千葉県) 国立がん研究センター中央病院(東京都) 神奈川県立病院機構神奈川県立がんセンター(神奈川県) 横浜市立大学附属市民総合医療センター(神奈川県) 新潟県立がんセンター新潟病院(新潟県) 富山大学附属病院(富山県) 金沢大学医学部(石川県) 静岡県立静岡がんセンター(静岡県) 大阪国際がんセンター(大阪府) 国立病院機構大阪医療センター(大阪府) 関西医科大学附属病院(大阪府) 兵庫医科大学(兵庫県) 兵庫県立がんセンター(兵庫県) 山口大学医学部附属病院(山口県) 国立病院機構四国がんセンター(愛媛県) 国立病院機構九州がんセンター(福岡県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 1237 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | This study is a multi-institutional retrospective observational study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000035302 |